AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will featur ...

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will featu ...

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress being held in San Francisco, California from February 6–8, 2025. Presentation DetailsFormat: Poster presen ...

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn’s and Colitis Congress being held in San Francisco, California from February 6–8, 2025. Presentation DetailsFormat: Poster prese ...

AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2575858 (State or other jurisdic ...

Financial Performance - Cash and cash equivalents and investments as of September 30, 2024, were approximately $90.1 million, down from $101.1 million as of September 30, 2023, representing a decrease of about 10.0%[2] - The net loss for Q3 2024 was $16.7 million, or $0.33 per share, compared to a net loss of $27.5 million, or $0.65 per share, in Q3 2023, indicating an improvement of 39.5%[2] - Total assets as of September 30, 2024, were approximately $111.7 million, down from $159.6 million as of December 31, 2023, a decrease of about 30.0%[8] - Total liabilities as of September 30, 2024, were $15.1 million, slightly up from $14.9 million as of December 31, 2023[8] Expenses - Research and Development (R&D) expenses for Q3 2024 were $16.3 million, a decrease of 32.0% compared to $24.2 million in Q3 2023[2] - General and Administrative (G&A) expenses for Q3 2024 were $4.6 million, down from $5.1 million in Q3 2023, reflecting a reduction of approximately 9.8%[2] Strategic Initiatives - The company announced the development of SL-325, a first-in-class DR3 antagonist antibody, with an IND filing expected in Q3 2025[1] - The company has completed its restructuring plans to focus on SL-325 and has substantially reduced its workforce associated with the discontinuation of SL-172154[3] Future Outlook - Shattuck Labs expects its cash and cash equivalents to fund operations into 2027, based on current operational plans[3] - The company plans to participate in investor conferences, including the Piper Sandler & Co. 36th Annual Healthcare Conference from December 3-5, 2024[2]

A downtrend has been apparent in Shattuck Labs, Inc. (STTK) lately with too much selling pressure. The stock has declined 64.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indic ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ: STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK. Investigation Details On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lea ...

Shattuck Labs, Inc. (STTK) has been on a downward spiral lately with significant selling pressure. After declining 69% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...